Gonzalez and others retrospectively analyzed Medicare data to investigate the differential effects of DPP4i, SGLT2i, and another class of antihyperglycemic agents, glucagon-like peptide-1 receptor agonists, on clinical outcomes in patients with diabetes and heart failure with reduced and preserved ejection fraction[14]. This evidence concerns the gene GLP1R and diabetes mellitus.